Skip to main content
Equibles

Tyler Van Buren

Analyst

TD Cowen

Equibles does not estimate personal net worth.

About Tyler Van Buren

Tyler Van Buren is recorded as Analyst at TD Cowen. Tyler Van Buren has spoken on 24 earnings calls and 9 other investor events across 16 companies, most recently for Iovance Biotherapeutics, Inc. on September 15, 2026. Those appearances were for Gilead Sciences, Inc. (GILD), BridgeBio Pharma, Inc. (BBIO), Allogene Therapeutics, Inc. (ALLO), Bicara Therapeutics Inc. (BCAX), Arcutis Biotherapeutics, Inc. (ARQT) and 11 other companies. The companies whose calls Tyler Van Buren spoke on are classified in the Healthcare sector.

Tyler Van Buren on recent calls

“Can you please elaborate on the big quarter-over-quarter jump in ProLukin revenue and the anticipated split of MTag B to ProLukin revenue moving forward? and if the gross margin can continue to improve quarter over quarter, despite ProLucan likely contributing to a smaller percentage of sales in subsequent quarters.”
Analyst — TD Cowen, H.C. Wainwright 28th Annual Global Investment Conference ·
“Congratulations on your first call as CEO, Zach, and appreciate the efficient, prepared remarks. I guess, given the acceleration of site activation by six months, is it possible that the interim EFS analysis could occur earlier than the guided mid-2027 timeline?”
Analyst — TD Cowen, The Allogene Therapeutics Second Quarter 2026 Conference Call ·
“Claire and Ivan, I too want to thank you and congratulate you for all of your accomplishments. You both will be missed. And I'd also like to congratulate Ryan, Tanya, Jen, Jenna, and Greg on their promotions.”
Analyst — TD Cowen, Bicara Therapeutics Inc. Q2 FY2026 Earnings Call ·
“It's great to see the more than 35 million in sequential U.S. revenue that Atruvi added again this quarter.”
Analyst — TD Cowen, BridgeBio Q2 Earnings Call ·
“First, just would it be reasonable to expect a similar quarter-over-quarter sales growth for this refranchise in Q3 over Q2 as compared to Q2 to over Q1 that we just saw?”
Analyst — TD Cowen, Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Conference Call ·

Affiliation history

  • TD Cowen

    Analyst

    Source not stated

    Current

Company network

Soleno Therapeutics Inc

Biotechnology · Healthcare

2 appearances Latest appearance 2026-03-04

Arcellx, Inc.

Biotechnology · Healthcare

1 appearance Latest appearance 2026-03-03

Crinetics Pharmaceuticals, Inc.

Biotechnology · Healthcare

1 appearance Latest appearance 2026-02-26

Recent activity

Show 21 earlier activities